Skip to content
Screener

UroGen Pharma URGN EPS (Diluted)

Discontinued — last reported Q2 '21

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Pfizer logo
PfizerPFE
-$0.04-108%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.27-0.9%
Merck & Co. logo
Merck & Co.MRK
-$0.54-131%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.62-313%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
-$0.50+9.1%

Other financials

Income statement

See full
Revenue$72.5M+199%
Net income-$14.4M+71.3%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$197.5M+55.0%
Total equity-$132.4M-41.8%
Total assets$252.6M+21.0%

Cash flow

See full
Operating cash flow-$33.0M+17.1%
CapEx$60.0K-57.4%
Free cash flow-$33.1M+17.3%

Valuation

See full
Market cap$2.13B+154%
Enterprise value$2.24B+157%
P/S11.3×+2.4×

Profitability

See full
Gross margin89.7%—
Operating margin-329.7%—
Net margin-51.7%-21.0pp
FCF margin-84.3%-22.2pp

Returns & leverage

See full
Return on equity-211.6%—
Debt / equity4.8×—
Current ratio3.8×-0.3×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasicAndDiluted.

The source filing: UroGen Pharma’s 10-Q, filed August 4, 2021. Open the filing →

Filed
Aug 4, 2021, 8:09 AM EDT
Fiscal quarter
Q2 FY2021
Calendar quarter
Q2 2021
Accession
0001564590-21-040510

FAQ

What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.